This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Covidien Prevails In Patent Action Against Applied Medical Resources

Covidien (NYSE: COV), a global healthcare products company, announced that it has prevailed against Applied Medical Resources, Inc. in a patent action before the United States Court of Appeals for the Federal Circuit.

In May 2011, Applied Medical sued Covidien in connection with Covidien’s sale of certain trocar products. On August 27, the United States Court of Appeals for the Federal Circuit affirmed the lower court’s previous ruling that Covidien’s trocar products do not infringe Applied Medical’s patent.

This is the fifth patent infringement action since 2000 that Applied Medical has brought against Covidien (and its predecessor companies) relating to trocars seals. Covidien has secured dismissal of all five of these actions.

“We are pleased the Court recognized that Covidien’s trocar products are differentiated from our competitors. As we have demonstrated, we will vigorously protect our innovative products, solutions and intellectual property,” stated Steve Blazejewski, President of Surgical Supplies, Covidien.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs